Sorrento Reports Promising Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device
Excerpt from the Press Release:
SAN DIEGO, Aug. 26, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19, today announced promising preclinical results for its mRNA vaccine against SARS-CoV-2. STI-mRNA is comprised of proprietary designer Spike-encoding mRNAs to elicit cellular and humoral immunity against the early WA-1 virus as well as the predominant and emerging variants of concern (VOCs), including Alpha, Beta, Gamma, Delta, and Lambda.
Currently marketed vaccines have demonstrated reduced efficacy against the major SARS-CoV-2 emerging VOCs2, with declining efficacy over time3. Novel approaches are needed that improve durability for both humoral and cellular immunity against current and emerging variants.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?